जर्नल ऑफ पल्मोनोलॉजी एंड रेस्पिरेटरी डिजीज

खुला एक्सेस

हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।

ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं

अमूर्त

In the Early Stages of the COVID-19 Epidemic, Weighing Evidence and First-Hand Experience

Levra S

Background: Severe acute respiratory pattern coronavirus 2(SARS- CoV- 2) is the causative agent of coronavirus complaint 2019(COVID- 19), which has fleetly come epidemic in Italy and other European countries. The complaint diapason ranges from asymptomatic/ mildly characteristic donations to acute respiratory failure. At the present time the absolute number of severe cases taking ventilator support is reaching or indeed surpassing the ferocious care unit bed capacity in the most affected regions and countries.

Objects: To narratively epitomize the available literature on the operation of COVID- 19 in order to combine current substantiation and frontline opinions and to give balanced answers to pressing clinical questions.

Sources: Inductive PubMed hunt for publications applicable to the content.

Content: The available literature and the authors' frontline- grounded opinion are epitomized in brief narrative answers to named clinical questions, with a conclusive statement handed for each answer.

Counteraccusations: Numerous off- marker antiviral andanti-inflammatory medicines are presently being administered to cases with COVID- 19. Physicians must be apprehensive that, as they aren't supported by highposition substantiation, these treatments may frequently be immorally maintainable only in those worsening cases doubtful to ameliorate only with probative care, and who cannot be enrolled onto randomized clinical trials. Access to well- designed randomized controlled trials should be expanded as much as possible because it's the most secure way to change for the better our approach to COVID- 19 cases.

अस्वीकृति: इस सारांश का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया है और इसे अभी तक समीक्षा या सत्यापित नहीं किया गया है।